{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T06:40:32Z","timestamp":1776753632098,"version":"3.51.2"},"update-to":[{"DOI":"10.1002\/14651858.cd008976","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,4,13]],"date-time":"2011-04-13T00:00:00Z","timestamp":1302652800000}}],"reference-count":41,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008976.pub2","type":"journal-article","created":{"date-parts":[[2011,4,13]],"date-time":"2011-04-13T17:57:24Z","timestamp":1302717444000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Gemcitabine for unresectable, locally advanced or metastatic bladder cancer"],"prefix":"10.1002","volume":"2011","author":[{"given":"Mike","family":"Shelley","sequence":"first","affiliation":[{"name":"Velindre NHS Trust; Cochrane Prostatic Diseases and Urological Cancers Unit, Research Dept; Velindre Road Whitchurch Cardiff Wales UK CF4 7XL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Cleves","sequence":"additional","affiliation":[{"name":"Cardiff University Velindre Hospital; Cancer Research Wales Library; Cardiff Wales UK CF14 2TL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J","family":"Wilt","sequence":"additional","affiliation":[{"name":"VAMC; General Internal Medicine (111-0); One Veterans Drive Minneapolis Minnesota USA 55417"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm","family":"Mason","sequence":"additional","affiliation":[{"name":"Velindre Hospital; Clinical Oncology; Whitchurch Cardiff UK CF4 7XL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,4,13]]},"reference":[{"issue":"supplement","key":"10.1002\/14651858.CD008976.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"Abstract 5030","DOI":"10.1200\/jco.2008.26.15_suppl.5030","article-title":"Randomised phase III trial of 2nd line gemcitabine paclitaxel chemotherapy in patients with advanced bladder cancer","volume":"26","author":"Albers","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"23","key":"10.1002\/14651858.CD008976.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.1200\/JCO.2008.21.4924","article-title":"Randomised phase II\/III trial assessing Gemcitabine\/Carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer 'unfit' for cisplatin-based chemotherapy: Phase II- results of EORTC study 30986","volume":"27","author":"Santis","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008976.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2006.12.029","article-title":"Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomised phase 2 trial","volume":"52","author":"Doglotti","year":"2007","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD008976.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1742-1241.2005.00663.x","article-title":"Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO trial AB 20\/99)","volume":"60","author":"Fechner","year":"2006","journal-title":"International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD008976.pub2-BIB0005|cit5","first-page":"283","article-title":"Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium","volume":"13","author":"Lorusso","year":"2005","journal-title":"Oncological Reports"},{"issue":"supplement 5","key":"10.1002\/14651858.CD008976.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/annonc\/mdj965","article-title":"Long-term survival results of a randomised trial comparing gemcitabine\/cisplatin and methotrexate\/vinblastine\/doxorubicin\/cisplatin in patients with locally advanced and metastatic bladder cancer","volume":"17","author":"Roberts","year":"2006","journal-title":"Annals of Oncology"},{"issue":"17","key":"10.1002\/14651858.CD008976.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomised, multinational, multicenter, phase III study","volume":"17","author":"de Masse","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD008976.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomised phase III trial on gemcitabine versus mitomycin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD008976.pub2-BIB0009|cit9","first-page":"283","article-title":"Gemcitabine versus BCG after initial BCG failure in non- muscle invasive bladder cancer: A prospective randomised trial","volume":"8","author":"Autorino","year":"2009","journal-title":"European Urology"},{"issue":"3","key":"10.1002\/14651858.CD008976.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.eururo.2009.06.010","article-title":"Single postoperative instillation of gemcitabine in patients with non-muscle invasive transitional cell carcinoma of the bladder: A randomised, double-blind, placebo-controlled Phase III multicentre study","volume":"56","author":"Bahle","year":"2009","journal-title":"European Urology"},{"issue":"4, Supplement S","key":"10.1002\/14651858.CD008976.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0022-5347(09)61930-3","article-title":"Single postoperative instillation of gemcitabine in patients with superficial transitional cell carcinoma of the bladder: A randomised, double-blind, placebo-controlled phase 3 multicenter study","volume":"181","author":"Boehle","year":"2009","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD008976.pub2-BIB0012|cit12","unstructured":"Carteni G Dogliotti L Crucitta E Proceedings of the American Society of Clinical Oncology Chicago, USA 2003 Abstract No 1543, page 384"},{"key":"10.1002\/14651858.CD008976.pub2-BIB0013|cit13","first-page":"Abstract No 502","article-title":"Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus Chemotherapy (CT) at relapse (CR) in patients with muscle-invasive bladder cancer submitted to radical cystectomy. An Italian multicentre randomised phase III trial","volume":"15S","author":"Cognoetti","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"10.1002\/14651858.CD008976.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejcsup.2008.06.049","article-title":"Intravesical gemcitabine versus mitomycin for recurrent superficial bladder tumours (Stages pTa and pT1): A randomised prospective study","volume":"6","author":"Faiola","year":"2008","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD008976.pub2-BIB0015|cit15","first-page":"284","article-title":"Randomised phase II trial of gemcitabine and paclitaxel with or without maintenance treatment in patients with cisplatin refractory transitional cell carcinoma","volume":"167","author":"Fechner","year":"2002","journal-title":"Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD008976.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.urology.2005.03.084","article-title":"Randomised phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent stage Ta urothelial cell carcinoma of the bladder","volume":"66","author":"Gardmark","year":"2005","journal-title":"Urology"},{"issue":"36","key":"10.1002\/14651858.CD008976.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1200\/JCO.2007.10.7078","article-title":"Randomised crossover study evaluating the effect of gemcitabine infusion dose rate: Evidence of auto-induction of gemcitabine accumulation","volume":"25","author":"Grimison","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008976.pub2-BIB0018|cit18","unstructured":"Khaled HM Zaghoul MS Ghoneim M A randomised phase II study of neoadjuvant chemotherapy for invasive bladder cancer with gemcitabine and cisplatin proceedings of the American Society of Clinical Oncology 2002 Abstract No 2421 page 152b"},{"issue":"8","key":"10.1002\/14651858.CD008976.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1007\/s00120-003-0317-4","article-title":"Gemcitabine\/cisplatin vs MVAC. Results after 5 years of the phase III study on the chemotherapy of advanced urothelial cancer in Germany","volume":"42","author":"Lehmann","year":"2003","journal-title":"Urologe A"},{"issue":"Supplement 5","key":"10.1002\/14651858.CD008976.pub2-BIB0020|cit20","first-page":"93","article-title":"A phase II randomised trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine - cisplatin in advanced transitional cell carcinoma of the urinary tract (TCC). A cooperative study of the IBCG (Italian Bladder Cancer Group)","volume":"55","author":"Lorusso","year":"2002","journal-title":"Annals of Oncology"},{"issue":"25","key":"10.1002\/14651858.CD008976.pub2-BIB0021|cit21","first-page":"4962","article-title":"Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium","volume":"27","author":"Milowski","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"16S (June 1 sup","key":"10.1002\/14651858.CD008976.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1200\/jco.2005.23.16_suppl.4589","article-title":"Preliminary cytogenetic and pharmacogenomic analysis of muscle-invasive transitional cell carcinoma (TCC) of the bladder in patients enrolled in the Italian National Research Council phase II randomised trial comparing adjuvant cisplatin gemcitabine vs observation after radical cystectomy","volume":"23","author":"Pollera","year":"2005","journal-title":"Journal Of Clinical Oncology"},{"key":"10.1002\/14651858.CD008976.pub2-BIB0023|cit23","doi-asserted-by":"crossref","unstructured":"Viellefond A Beuzeboc P Mignot L HER2 status in urothelial bladder cancer (UC): screening of patients eligible for a phase II randomised study of gemcitabine plus platinum salt with or without tratuzumab Annual Meeting Proceedings of the American Society of Clinical Oncology Orlando USA 2005 Abstract No 47000, page 427","DOI":"10.1200\/jco.2005.23.16_suppl.4700"},{"issue":"21","key":"10.1002\/14651858.CD008976.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomised trial comparing gemcitabine plus cisplatin with methotrexate, vinblastine, doxorubicin and cisplatin in patients with bladder cancer","volume":"23","author":"Masse","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"145","key":"10.1002\/14651858.CD008976.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/jco.2004.22.90140.4626","article-title":"Adjuvant chemoradiotherapy with gemcitabine and cisplatin and postoperative radiotherapy (PORT) versus PORT alone in high risk bladder cancer patients. A phase III randomised trial","volume":"22","author":"Zaghiuol","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008976.pub2-BIB0026|cit26","unstructured":"Cancer Research UK Bladder Cancer http:\/\/info.cancerresearchuk.org\/cancerstats\/types\/bladder (Accessed August 2010) 2009"},{"key":"10.1002\/14651858.CD008976.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/cncr.22454","article-title":"Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function","volume":"109","author":"Galsky","year":"2007","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD008976.pub2-BIB0028|cit28","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"key":"10.1002\/14651858.CD008976.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.2001.19.9.2527","article-title":"Combination paclitaxel, carboplatin and gemcitabine is an active treatment for advanced bladder cancer","volume":"19","author":"Hussain","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008976.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/sj.bjc.6602112","article-title":"A phase I\/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21 day schedule in patients with advanced and metastatic bladder cancer","volume":"91","author":"Hussain","year":"2004","journal-title":"British Journal of Cancer"},{"issue":"16","key":"10.1002\/14651858.CD008976.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1200\/JCO.2006.08.0994","article-title":"Trastuzumab, paclitaxel, carboplatin and gemcitabine in advanced human epithelial growth factor receptor-2\/nue- positive urothelial carcinoma: results of a multicenter phase II national cancer institute trial","volume":"25","author":"Hussain","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008976.pub2-BIB0032|cit32","first-page":"43","article-title":"Cancer Statistics","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD008976.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1200\/JCO.2000.18.9.1921","article-title":"Phase II trial of Gemcitabine plus cisplatin in patients with metastatic urothelial cancer","volume":"8","author":"Kaufman","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008976.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomised comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study","volume":"10","author":"Loehrer","year":"1992","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008976.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.1990.8.6.1050","article-title":"A prospective randomised trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumours","volume":"8","author":"Logothesis","year":"1990","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008976.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.1997.15.12.3441","article-title":"Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer","volume":"15","author":"Moore","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"Supplementum","key":"10.1002\/14651858.CD008976.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/03008880802285032","article-title":"The global burden of urinary bladder cancer","volume":"218","author":"Parkin","year":"2008","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD008976.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1586\/14737167.4.1.27","article-title":"Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer","volume":"4","author":"Robinson","year":"2004","journal-title":"Expert Reviews in Pharmacoeconomics Outcomes Research"},{"key":"10.1002\/14651858.CD008976.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1200\/JCO.2002.20.5.1361","article-title":"Phase III trial of fluorouracil, interferon alfa-2b and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in metastatic or unresectable urothelial cancer","volume":"20","author":"Siefket-Radtke","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008976.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","article-title":"Randomised phase III trial of high dose intensity methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony stimulating factor versus classic MVAC in advanced urothelial tumours: European Organisation for Research and Treatment of Cancer protocol no. 30924","volume":"19","author":"Sternberg","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008976.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","article-title":"Phase I study of single agent Gemcitabine in previously untreated patients with metastatic urothelial cancer","volume":"15","author":"Stradler","year":"1997","journal-title":"Journal of Clinical Oncology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008976.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T18:31:36Z","timestamp":1774895496000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008976.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Urology Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,4,13]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2011,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008976.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,13]]}}}